United Kingdom· GB-APID-37439611000001101
Incruse Ellipta 55micrograms/dose dry powder inhaler
A medicinal product containing umeclidinium bromide, registered in United Kingdom by CST Pharma Ltd.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Umeclidinium bromide
- Manufacturer
- CST Pharma Ltd
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5055946802015
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Umeclidinium bromide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaINCRUSE ELLIPTAGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumElebrato Ellipta 92 µg/dose - 22 µg/doseGlaxoSmithKline Trading Services
- SpainINCRUSE ELLIPTA 55 mcg POLVO PARA INHALACION UNIDOSISGlaxosmithkline Trading Services Limited
- FinlandIncruse ElliptaGlaxoSmithKline Trading Services Limited
- NetherlandsIncruse Ellipta 55 microgram inhalatiepoeder, voorverdeeldGlaxoSmithKline Trading Services Limited
- United StatesIncruse ElliptaGlaxoSmithKline LLC
- SwitzerlandIncruse Ellipta
- IrelandIncruse Ellipta 55 micrograms inhalation powder, pre-dispensedGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Incruse Ellipta, Rolufta Ellipta
- Liechtenstein · Incruse Ellipta, Rolufta Ellipta
- Norway · Incruse Ellipta, Rolufta Ellipta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6d6d4b1f-11cb-46bf-a98b-71ae1bbc15cc GET /v1/drugs/6d6d4b1f-11cb-46bf-a98b-71ae1bbc15cc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "37439611000001101",
"desc": "Incruse Ellipta 55micrograms/dose dry powder inhaler (CST Pharma Ltd)",
"form": "Inhalation powder",
"vpid": "27890611000001109",
"source": "dmd",
"vtm_id": "27896111000001103",
"strength": "65 microgram",
"substance": "Umeclidinium bromide",
"ingredient": "Umeclidinium bromide",
"supplier_code": "24059811000001102"
}See everything about umeclidinium bromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.